BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, Wong F, Kim WR. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021;74:1014-48. [PMID: 33942342 DOI: 10.1002/hep.31884] [Cited by in Crossref: 75] [Cited by in F6Publishing: 81] [Article Influence: 75.0] [Reference Citation Analysis]
Number Citing Articles
1 Enomoto H, Takashima T, Nishimura T, Aizawa N, Ikeda N, Yuri Y, Okamoto M, Yoshihara K, Yoshioka R, Kawata S, Ota S, Nakano R, Shiomi H, Iijima H. Liver cirrhosis in Japan: Future global trends in the era of progressive antiviral therapy. Portal Hypertension & Cirrhosis 2022. [DOI: 10.1002/poh2.30] [Reference Citation Analysis]
2 Du X, Wei X, Ma L, Liu X, Guo H, Liu Y, Zhang J. Higher levels of neutrophil percentage-to-albumin ratio predict increased mortality risk in patients with liver cirrhosis: a retrospective cohort study. European Journal of Gastroenterology & Hepatology 2022;Publish Ahead of Print. [DOI: 10.1097/meg.0000000000002470] [Reference Citation Analysis]
3 Xiao N, Liu L, Zhang Y, Nie Y, Zhu X. A practical nomogram based on serum interleukin-6 for the prognosis of liver failure. Front Med 2022;9. [DOI: 10.3389/fmed.2022.1035699] [Reference Citation Analysis]
4 Fortea JI, Crespo J, Puente Á. Cirrhosis, a Global and Challenging Disease. JCM 2022;11:6512. [DOI: 10.3390/jcm11216512] [Reference Citation Analysis]
5 Hughes JA, Bishop TH, Mcloney ED, Thomas SL, Wessinger JM. Large volume paracentesis of 39.5 liters chylous ascites in the setting of high-grade follicular lymphoma. Radiology Case Reports 2022;17:4276-4279. [DOI: 10.1016/j.radcr.2022.08.036] [Reference Citation Analysis]
6 Wu HHL, Athwal VS, Kalra PA, Chinnadurai R. COVID-19 and hepatorenal syndrome. World J Gastroenterol 2022; 28(39): 5666-5678 [DOI: 10.3748/wjg.v28.i39.5666] [Reference Citation Analysis]
7 Singal AK, Kuo YF, Reddy KR, Bataller R, Kwo P. Healthcare burden and outcomes of hepatorenal syndrome among cirrhosis-related hospitalisations in the US. Aliment Pharmacol Ther 2022. [PMID: 36196562 DOI: 10.1111/apt.17232] [Reference Citation Analysis]
8 Ness BM, Brown SE. Fluid Overload. Critical Care Nursing Clinics of North America 2022. [DOI: 10.1016/j.cnc.2022.07.001] [Reference Citation Analysis]
9 Reau N, Munoz SJ, Schiano T. Liver Disease During Pregnancy. Am J Gastroenterol 2022;117:44-52. [DOI: 10.14309/ajg.0000000000001960] [Reference Citation Analysis]
10 Ajmera V, Kim BK, Yang K, Majzoub AM, Nayfeh T, Tamaki N, Izumi N, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Quach NE, Tu X, Zhang X, Noureddin M, Allen AM, Loomba R. Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants. Gastroenterology 2022;163:1079-1089.e5. [PMID: 35788349 DOI: 10.1053/j.gastro.2022.06.073] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
11 Regner KR, Kanduri SR, Velez JCQ. Management of AKI in Patients with Cirrhosis. Curr Treat Options Gastro 2022;20:295-315. [DOI: 10.1007/s11938-022-00398-7] [Reference Citation Analysis]
12 Zhu CX, Yang L, Zhao H, Zhang Y, Tu S, Guo J, Yan D, Hu CX, Lu HF, Xu KJ, Huang JR, Li LJ. Impact of cirrhosis-related complications on posttransplant survival in patients with acute-on-chronic liver failure. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00205-3. [PMID: 36151023 DOI: 10.1016/j.hbpd.2022.09.004] [Reference Citation Analysis]
13 de Mattos ÂZ, Simonetto DA, Terra C, Farias AQ, Bittencourt PL, Pase THS, Toazza MR, de Mattos AA, Alliance of Brazilian Centers for Cirrhosis Care – the ABC Group. Albumin administration in patients with cirrhosis: Current role and novel perspectives. World J Gastroenterol 2022; 28(33): 4773-4786 [DOI: 10.3748/wjg.v28.i33.4773] [Reference Citation Analysis]
14 Alshuwaykh O, Cheung A, Goel A, Kwong A, Dhanasekaran R, Ghaziani TT, Ahmed A, Daugherty T, Dronamraju D, Kumari R, Nguyen M, Kim WR, Kwo PY. Clinical characteristics and outcomes in those with primary extrahepatic malignancy and malignant ascites. BMC Gastroenterol 2022;22:410. [PMID: 36064324 DOI: 10.1186/s12876-022-02487-4] [Reference Citation Analysis]
15 Divens LL, Rivera SL. Hepatorenal Syndrome. Critical Care Nursing Clinics of North America 2022;34:321-9. [DOI: 10.1016/j.cnc.2022.04.010] [Reference Citation Analysis]
16 Saffo S, Garcia-tsao G. Early mechanical ventilation for grade IV hepatic encephalopathy is associated with increased mortality among patients with cirrhosis: an exploratory study. Acute Crit Care 2022;37:355-362. [DOI: 10.4266/acc.2022.00528] [Reference Citation Analysis]
17 Wu H, Hou W, Zhang W, Wang Z, Guo S, Chen D, Li Z, Wei F, Hu Z. Clinical evaluation of bacterial DNA using an improved droplet digital PCR for spontaneous bacterial peritonitis diagnosis. Front Cell Infect Microbiol 2022;12:876495. [DOI: 10.3389/fcimb.2022.876495] [Reference Citation Analysis]
18 Wei X, Du X, Liu Y, Wu J, Zhang J. High plasma soluble thrombomodulin levels indicated poor prognosis of decompensated liver cirrhosis: a prospective cohort study. Eur J Gastroenterol Hepatol 2022. [PMID: 35946457 DOI: 10.1097/MEG.0000000000002428] [Reference Citation Analysis]
19 Muciño-bermejo M. Extracorporeal organ support and the kidney. Front Nephrol 2022;2. [DOI: 10.3389/fneph.2022.924363] [Reference Citation Analysis]
20 Seshadri A, Appelbaum R, Carmichael SP, Cuschieri J, Hoth J, Kaups KL, Kodadek L, Kutcher ME, Pathak A, Rappold J, Rudnick SR, Michetti CP. Management of Decompensated Cirrhosis in the Surgical ICU: an American Association for the Surgery of Trauma Critical Care Committee Clinical Consensus Document. Trauma Surg Acute Care Open 2022;7:e000936. [DOI: 10.1136/tsaco-2022-000936] [Reference Citation Analysis]
21 Amin AN, Nguyen PH, Tapper EB. Missed diagnosis of cirrhosis in the inpatient setting. J Hosp Med 2022;17 Suppl 1:S1-7. [PMID: 35972039 DOI: 10.1002/jhm.12918] [Reference Citation Analysis]
22 Weil-Verhoeven D, Di Martino V, Stirnimann G, Cervoni JP, Nguyen-Khac E, Thévenot T. Alfapump® implantable device in management of refractory ascites: An update. World J Hepatol 2022; 14(7): 1344-1356 [DOI: 10.4254/wjh.v14.i7.1344] [Reference Citation Analysis]
23 Yao W, Liu JC, Wu YJ, Yang CT, Ju SG, Wang YL, Wang CY, Huang SJ, Bai YW, Chen Y, Li TQ, Zhou C, Xiong B. Effect of underdilated transjugular intrahepatic portosystemic shunt on prognosis in patients with prior splenectomy: a propensity score-matched case-control study. Abdom Radiol (NY) 2022. [PMID: 35821274 DOI: 10.1007/s00261-022-03600-7] [Reference Citation Analysis]
24 Nobbe AM, Mccurdy HM. Management of the Adult Patient with Cirrhosis Complicated by Ascites. Critical Care Nursing Clinics of North America 2022. [DOI: 10.1016/j.cnc.2022.04.005] [Reference Citation Analysis]
25 Pitre T, Kiflen M, Helmeczi W, Dionne JC, Rewa O, Bagshaw SM, Needham-Nethercott N, Alhazzani W, Zeraatkar D, Rochwerg B. The Comparative Effectiveness of Vasoactive Treatments for Hepatorenal Syndrome: A Systematic Review and Network Meta-Analysis. Crit Care Med 2022. [PMID: 35777925 DOI: 10.1097/CCM.0000000000005595] [Reference Citation Analysis]
26 Pippard B, Bhatnagar M, McNeill L, Donnelly M, Frew K, Aujayeb A. Hepatic Hydrothorax: A Narrative Review. Pulm Ther 2022. [PMID: 35751800 DOI: 10.1007/s41030-022-00195-8] [Reference Citation Analysis]
27 Alexander E, Weatherhead J, Creo A, Hanna C, Steien DB. Fluid management in hospitalized pediatric patients. Nutr Clin Pract 2022. [PMID: 35748381 DOI: 10.1002/ncp.10876] [Reference Citation Analysis]
28 Bera C, Wong F. Management of hepatorenal syndrome in liver cirrhosis: a recent update. Therap Adv Gastroenterol 2022;15:17562848221102679. [PMID: 35721838 DOI: 10.1177/17562848221102679] [Reference Citation Analysis]
29 Kalo E, Sheriff N, Isaac M, Baig A, Read S, Ahlenstiel G. A Call for Implementation of an Evidence-Based, Quality Improvement, Decompensated Cirrhosis Discharge Care Bundle in Australia. Livers 2022;2:97-104. [DOI: 10.3390/livers2020007] [Reference Citation Analysis]
30 Lotte R, Courdurié A, Gaudart A, Emery A, Chevalier A, Tran A, Payen M, Ruimy R. Spontaneous Bacterial Peritonitis: The Incremental Value of a Fast and Direct Bacterial Identification from Ascitic Fluids Inoculated in Blood Culture Bottles by MALDI-TOF MS for a Better Management of Patients. Microorganisms 2022;10:1188. [PMID: 35744706 DOI: 10.3390/microorganisms10061188] [Reference Citation Analysis]
31 Song Y, Wang Y, Zang C, Yang X, Li Z, Wu L, Li K. Prognostic Nomograms for Hospital Survival and Transplant-Free Survival of Patients with Hepatorenal Syndrome: A Retrospective Cohort Study. Diagnostics 2022;12:1417. [DOI: 10.3390/diagnostics12061417] [Reference Citation Analysis]
32 Tergast TL, Griemsmann M, Stockhoff L, Heidrich B, Schirmer H, Lenzen H, Wedemeyer H, Cornberg M, Jaeckel E, Maasoumy B. Home-based, tunnelled peritoneal drainage system as an alternative treatment option for patients with refractory ascites. Aliment Pharmacol Ther 2022. [PMID: 35656633 DOI: 10.1111/apt.17066] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
33 Ferreira LM, Terrabuio DR, Ferreira CM, Mazo DFDC, Haddad LBDP. COST EFFECTIVENESS OF USING TERLIPRESSIN TO TREAT HEPATORENAL SYNDROME. Arq Gastroenterol 2022;59:268-274. [DOI: 10.1590/s0004-2803.202202000-48] [Reference Citation Analysis]
34 Kaplan A, Rosenblatt R. Symptom Management in Patients with Cirrhosis: a Practical Guide. Curr Treat Options Gastro 2022;20:144-159. [DOI: 10.1007/s11938-022-00377-y] [Reference Citation Analysis]
35 Caraceni P, O'Brien A, Gines P. Long-term albumin treatment in patients with cirrhosis and ascites. J Hepatol 2022;76:1306-17. [PMID: 35589252 DOI: 10.1016/j.jhep.2022.03.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
36 Bajaj JS, Ng SC, Schnabl B. Promises of microbiome-based therapies. J Hepatol 2022;76:1379-91. [PMID: 35589257 DOI: 10.1016/j.jhep.2021.12.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
37 Rondón-carvajal J, Alvarez-payares JC, Arias-madrid N, Echeverri-villegas J, Uribe-zapata L. Young Man With Non-hypertensive Ascites of Unexpected Cause: When Ockham’s Razor Is Not Sufficient. Cureus 2022. [DOI: 10.7759/cureus.25385] [Reference Citation Analysis]
38 Abdelhafez M, Nayfeh T, Atieh A, AbuShamma O, Babaa B, Baniowda M, Hrizat A, Hasan B, Hassett L, Hamadah A, Gharaibeh K. Diagnostic Performance of Fractional Excretion of Sodium for the Differential Diagnosis of Acute Kidney Injury: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2022:CJN. [PMID: 35545442 DOI: 10.2215/CJN.14561121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
39 Napoleone L, Solé C, Juanola A, Ma AT, Carol M, Pérez-Guasch M, Rubio AB, Cervera M, Avitabile E, Bassegoda O, Gratacós-Ginès J, Morales-Ruiz M, Fabrellas N, Graupera I, Pose E, Crespo G, Solà E, Ginès P. Patterns of kidney dysfunction in acute-on-chronic liver failure: Relationship with kidney and patients' outcome. Hepatol Commun 2022. [PMID: 35535681 DOI: 10.1002/hep4.1963] [Reference Citation Analysis]
40 Osman KT, Abdelfattah AM, Mahmood SK, Elkhabiry L, Gordon FD, Qamar AA. Refractory Hepatic Hydrothorax Is an Independent Predictor of Mortality When Compared to Refractory Ascites. Dig Dis Sci 2022. [PMID: 35534742 DOI: 10.1007/s10620-022-07522-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Tapper EB, Ufere NN, Huang DQ, Loomba R. Review article: current and emerging therapies for the management of cirrhosis and its complications. Aliment Pharmacol Ther 2022;55:1099-115. [PMID: 35235219 DOI: 10.1111/apt.16831] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Osman KT, Mehta N, Spencer C, Qamar AA. Spontaneous bacterial empyema: a tertiary care center experience and a systematic review. Expert Rev Gastroenterol Hepatol 2022;16:487-92. [PMID: 35392755 DOI: 10.1080/17474124.2022.2064274] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Ajmera V, Nguyen K, Tamaki N, Sharpton S, Bettencourt R, Loomba R. Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2022;15:175628482210938. [DOI: 10.1177/17562848221093869] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Hu SC, Xia H, Ye QQ, Xia C, Xu YL, Xiang XJ, Ma HZ, Gao XF, Chen HB. Reversal of hepatorenal syndrome and kidney recovery: When renal has more to offer. Semin Dial 2022. [PMID: 35460110 DOI: 10.1111/sdi.13083] [Reference Citation Analysis]
45 Cannella R, Tselikas L, Douane F, Cauchy F, Rautou P, Duran R, Ronot M. Imaging-guided interventions modulating portal venous flow: evidence and controversies. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100484] [Reference Citation Analysis]
46 Núñez I, Solis-huerta F, Soto-mota A. Serum-ascites albumin gradient – A false dichotomy in the approach to ascites. European Journal of Internal Medicine 2022. [DOI: 10.1016/j.ejim.2022.04.010] [Reference Citation Analysis]
47 Buccheri S, Da BL. Hepatorenal Syndrome. Clinics in Liver Disease 2022. [DOI: 10.1016/j.cld.2022.01.002] [Reference Citation Analysis]
48 Mazumder NR, Kazen A, Carek A, Etemadi M, Levitsky J. The answer at our fingertips: Volume status in cirrhosis determined by machine learning and pulse oximeter waveform. Physiol Rep 2022;10:e15223. [PMID: 35274819 DOI: 10.14814/phy2.15223] [Reference Citation Analysis]
49 Kulkarni AV, Rabiee A, Mohanty A. Management of Portal Hypertension. Journal of Clinical and Experimental Hepatology 2022. [DOI: 10.1016/j.jceh.2022.03.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
50 Aby ES, Lall D, Vasdev A, Mayer A, Olson APJ, Lim N. Rates of timely paracentesis for patients admitted to hospital with cirrhosis and ascites remain low but are unaffected by the COVID‐19 pandemic. Journal of Hospital Medicine. [DOI: 10.1002/jhm.12797] [Reference Citation Analysis]
51 Napolitano LM. Intra-abdominal Infections. Semin Respir Crit Care Med 2022;43:10-27. [PMID: 35172355 DOI: 10.1055/s-0041-1741053] [Reference Citation Analysis]
52 Rogal SS, Hansen L, Patel A, Ufere NN, Verma M, Woodrell CD, Kanwal F. AASLD Practice Guidance: Palliative care and symptom-based management in decompensated cirrhosis. Hepatology 2022. [PMID: 35103995 DOI: 10.1002/hep.32378] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
53 Hiffa A, Schulte K, Saeed M, Gani I. Massive Chylous Ascites After Living Donor Nephrectomy Successfully Treated With Lymphatic Embolization. J Investig Med High Impact Case Rep 2022;10:23247096211065631. [PMID: 35038891 DOI: 10.1177/23247096211065631] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
54 Dhanani M, Krishnamoorthy A, Ciolino JD, Gupta K, Strymish JM. Prophylaxis against spontaneous bacterial peritonitis: Too much or too little? ASHE 2022;2:e95. [DOI: 10.1017/ash.2022.232] [Reference Citation Analysis]
55 Moctezuma-velazquez C, Castro-narro G, Simó P, Viayna E, Aceituno S, Soler M, Torre A. Economic evaluation of long-term albumin use in cirrhosis patients from the Mexican healthcare system perspective. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100673] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Yoshino O. Liver Dysfunction and Failure: Clinical Presentation, Pathophysiology, and Management. Postinjury Multiple Organ Failure 2022. [DOI: 10.1007/978-3-030-92241-2_13] [Reference Citation Analysis]
57 Wong F, Sauerbruch T. Terlipressin in Liver Cirrhosis. Pharmacotherapy for Liver Cirrhosis and Its Complications 2022. [DOI: 10.1007/978-981-19-2615-0_10] [Reference Citation Analysis]
58 Kaewput W, Thongprayoon C, Dumancas CY, Kanduri SR, Kovvuru K, Kaewput C, Pattharanitima P, Petnak T, Lertjitbanjong P, Boonpheng B, Wijarnpreecha K, Zabala Genovez JL, Vallabhajosyula S, Jadlowiec CC, Qureshi F, Cheungpasitporn W. In-hospital mortality of hepatorenal syndrome in the United States: Nationwide inpatient sample. World J Gastroenterol 2021; 27(45): 7831-7843 [PMID: 34963745 DOI: 10.3748/wjg.v27.i45.7831] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
59 Giri S, Kasturi S, Darak H. Albumin for AKI in cirrhosis - Sham therapy or effective? Liver Int 2022;42:258-9. [PMID: 34817914 DOI: 10.1111/liv.15114] [Reference Citation Analysis]
60 Zaccherini G, Tufoni M, Iannone G, Caraceni P. Management of Ascites in Patients with Cirrhosis: An Update. J Clin Med 2021;10:5226. [PMID: 34830508 DOI: 10.3390/jcm10225226] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
61 Bajaj JS, Garcia-Tsao G, Kamath PS, O'Leary JG, Reddy KR, Wong F. REPLY. Hepatology 2021;74:2916-7. [PMID: 34110034 DOI: 10.1002/hep.32006] [Reference Citation Analysis]
62 Rabiee A. One Year After First Spontaneous Bacterial Peritonitis: Who Survives? J Clin Transl Hepatol 2021;9:603-4. [PMID: 34722173 DOI: 10.14218/JCTH.2021.00285] [Reference Citation Analysis]
63 Ioannou P, Karakonstantis S, Schouten J, Kostyanev T, Charani E, Vlahovic-Palcevski V, Kofteridis DP; supported by the ESCMID Study Group for Antimicrobial Stewardship (ESGAP). Indications for medical antibiotic prophylaxis and potential targets for antimicrobial stewardship intervention: a narrative review. Clin Microbiol Infect 2021:S1198-743X(21)00569-3. [PMID: 34653572 DOI: 10.1016/j.cmi.2021.10.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
64 Mayerhöfer T, Wiedermann CJ, Joannidis M. [Use of albumin : State of the art]. Med Klin Intensivmed Notfmed 2021;116:655-64. [PMID: 34618163 DOI: 10.1007/s00063-021-00875-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
65 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
66 Solé C, Ma AT, Solà E, Carol M, Fabrellas N, Juanola A, Napoleone L, Gratacós-Ginès J, Bassegoda O, Cervera M, Pérez M, Rubio AB, Avitabile E, Morales-Ruiz M, Graupera I, Pose E, Kamath PS, Ginès P. Sequential changes in urinary biomarker levels in patients with cirrhosis and severe hepatorenal syndrome. Liver Int 2021;41:2729-32. [PMID: 34569697 DOI: 10.1111/liv.15069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Yoo JJ, Kwon JH, Kim YS, Nam SW, Park JW, Kim HY, Kim CW, Shin SK, Chon YE, Jang ES, Jeong SH, Lee JW, Song DS, Yang JM, Lee SW, Lee HL, Jung YK, Yim HJ, Lee B, Kim SG, Kim JH. The Role of Urinary N-Acetyl-β-d-glucosaminidase in Cirrhotic Patients with Acute Kidney Injury: Multicenter, Prospective Cohort Study. J Clin Med 2021;10:4328. [PMID: 34640346 DOI: 10.3390/jcm10194328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
68 Wong YJ, Kumar R. Follow-Up Paracentesis in Spontaneous Bacterial Peritonitis: Prognostic, but May Not Improve Survival. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00840-5. [PMID: 34371164 DOI: 10.1016/j.cgh.2021.08.006] [Reference Citation Analysis]
69 Khemichian S, Francoz C, Nadim MK. Advances in management of hepatorenal syndrome. Curr Opin Nephrol Hypertens 2021;30:501-6. [PMID: 34397647 DOI: 10.1097/MNH.0000000000000730] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Paine CH, Pichler RH, Evans L, Biggins SW. Toward Norepinephrine as a First-Line Treatment for All Hospitalized Patients With Hepatorenal Syndrome. Liver Transpl 2021;27:1087-8. [PMID: 34028156 DOI: 10.1002/lt.26106] [Reference Citation Analysis]